ARM-002 / Defence Therap - LARVOL DELTA

Health4Her (H4H): a novel, scalable client-designed digital brief intervention to improve alcohol-breast cancer literacy among women attending breast screening services (EUSOBI 2024) - P=N/A | "Between t0 and t1, change in intentions to reduce alcohol consumption was significantly greater in the H4H-A arm (b=0.65, p<0.001, 95% CI 0.45, 0.85) compared to control (b=0.29, p=0.004, 95% CI 0.09, 0.48) (arm x time: p=0.011)...Alcohol literacy also significantly increased between t0 and t1 for the pilot arm.Figure 1 Change in intentions to reduce alcohol consumptionFigure 2 Change in the proportion of participants who identified alcohol as a clear risk factor for breast cancerFindings show the co-designed H4H-A intervention, delivered in-clinic or offsite, is effective in increasing women's intentions to reduce alcohol consumption, and increases alcohol literacy including awareness of the alcohol-breast cancer link. Our digital intervention has the potential to be scaled-up for implementation in other breast screening services and to empower women to make informed decisions."

Clinical • Breast Cancer • Oncology • Solid Tumor

Thoracoscopic pulmonary resection combined with real-time image-guided percutaneous ablation for multiple pulmonary nodules: a novel surgical approach and literature review. (PubMed, J Thorac Dis) - "Hybrid surgery of simultaneous pulmonary resection and ablation were performed in these patients to treat 2 to 4 pulmonary nodules, assisted by intraoperative real-time guide of C-arm X-ray machine...Patients had less loss of pulmonary function, fewer perioperative complications, and favorable oncologic prognosis. Hybrid surgery is expected to be a better treatment option for patients with sMPLC."

Journal • Review • Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor

Defence’s ARM-X Anti-Cancer Vaccine Inhibits Growth of Pre-Established Ovarian Cancer Resulting in Complete Responses in Treated Animals (Yahoo Finance) - "Defence Therapeutics Inc...is pleased to announce that its second-generation ARM-X anti-cancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with the anti-PD-1 immune-checkpoint inhibitor....The latter group prolonged animal survival beyond 80 days post-vaccination, and it led to a complete response in almost all treated animals..."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor